Skip to content

The Expression Line Peptide

Argireline

Also known as Acetyl hexapeptide-8

Summary coverage

At a glance

What it is
A topical neurotransmitter peptide aimed at expression lines.
Evidence
Practitioner experience onlyHow the tiers workOur material names Argireline as the anti-aging peptide for expression lines but cites no study, concentration or protocol for it. Why this tier
Half-life
Not established in available literature
Routes
Topical
Category
Skin
FDA
Not nominated
As of 3 August 2026. What that means
WADA
We do not state a status

Not schedulable in Claritide. Our sources publish no dosing figure for Argireline, so there is nothing to build a schedule from.

Evidence

Why this tier

Our material names Argireline as the anti-aging peptide for expression lines but cites no study, concentration or protocol for it.

Overview

What it is

Argireline is described in our material as a neurotransmitter peptide that relaxes the facial muscles responsible for expression lines: forehead lines and crow's feet specifically. It is listed as one of several anti-aging peptides targeting different mechanisms. Our sources publish no concentration, protocol or side effect data for it.

Mechanism

How it works

Our material classifies Argireline as a neurotransmitter peptide that relaxes the muscles that create expression lines. Expression lines are the creases formed by repeated muscle contraction rather than by loss of structural protein, which makes them a different target from the collagen-driven changes GHK-Cu and Matrixyl 3000 address. Our sources do not describe the receptor or signalling detail beyond this classification.

Dosing

Commonly researched ranges

These are figures reported in published literature and practitioner protocols: a commonly researched range, not a recommendation. Claritide does not tell you what to take.

Not established in available literature. Our sources describe Argireline without publishing a dosing figure, so Claritide does not print one.

Cycle guidance
Not established in available literature
Goals
Skin & hair
Legal standing

Where this sits with the FDA

Dated, sourced, and separate from whether it works. Removal from a warning list is not permission to compound.
Not nominatedas of 3 August 2026 · US

Regulated as a cosmetic ingredient rather than as a drug. It does not appear on FDA’s compounding category lists or the 503A bulks list.

Primary source
Sport

WADA status

The 2026 Prohibited List entered force on 1 January 2026.
We do not state a status

Not named on the 2026 List. A cosmetic ingredient rather than a pharmacological substance in the S0 sense; we do not state a status.

We looked and could not resolve it. This is not the same as "not prohibited". Treat it as unresolved and check with your federation before competing.

Reconstitution

There is nothing to mix

Not applicable. None of the published routes for this compound take a diluent, so there is no concentration to calculate and no beyond-use window to track.

Expectations

Week by week

What our material describes people reporting. Individual responses vary widely.

Not established in available literature.

Tolerability

Side effects

Grouped by how often our sources report them. Percentages appear only where a published trial figure exists.

Not established in available literature. Absence from this page does not mean absence of risk. It means our sources publish no side-effect profile for Argireline.

Safety

Contraindications and interactions

Do not use if

  • Our sources do not publish a contraindication list for Argireline

Interactions

Not established in available literature.

Absence from this list does NOT mean safety. It means lack of research.

Handling

Storage and cost

Storage
Topical formulations follow the manufacturer storage instructions. Our sources publish no specific storage guidance for Argireline.
Cost
Not established in available literature
Combinations

Stacks with

Only pairings our own material actually documents. Stacking is the least evidence-based part of this field.
Deep dive

Argireline in full

Limited coverage

Argireline appears in the anti-aging comparison table on our GHK-Cu page and in two FAQ answers there. We cite no study, no concentration, no application protocol and no side effect data.

What our sources do say

The table gives its role as "neurotransmitter peptide · relaxes expression muscles" and its best use as "forehead lines, crow's feet". Our GHK-Cu FAQ lists it in a multi-mechanism approach: "GHK-Cu leads for overall skin remodeling and gene-level anti-aging. Matrixyl 3000 for collagen signaling. Argireline for expression lines."

Why the mechanism distinction matters

Expression lines are not the same problem as skin ageing generally.

The lines GHK-Cu and Matrixyl 3000 address are structural: they come from declining collagen, elastin and dermal density. The intervention is to rebuild the material.

Expression lines come from repeated muscle contraction creasing the skin above it. Forehead lines and crow's feet are the canonical examples. Argireline, as our material classifies it, works on the muscle rather than the dermis.

That is a genuinely different target, which is why our anti-aging content presents these three as complementary rather than competing. Choosing between them is a category error; they address separate mechanisms.

What we cannot tell you

No concentration, no application frequency, no timeline, no compatibility notes, no side effects. Our published material never examined Argireline in detail, and this record does not pretend otherwise.

References

Sources

This record is built from our own guides and comparison tables, which cite no primary literature for Argireline. That is itself worth knowing.

Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.